诊断学理论与实践

诊断学理论与实践 >

2025 , Vol. 24 >Issue 02: 178 - 186

DOI: https://doi.org/10.16150/j.1671-2870.2025.02.009

论著

滤泡合并弥漫大B细胞淋巴瘤的PET/CT特征及其联合IPI在预后评估中的价值

  • 李卓含 ,
  • 黄新韵 ,
  • 郭睿 ,
  • 易红梅 ,
  • 许彭鹏 ,
  • 武志芳 ,
  • 李彪
展开
  • 1.山西医科大学第一医院核医学科，山西医科大学分子影像精准诊疗省部共建协同创新中心，山西 太原 030001
    2a.上海交通大学医学院附属瑞金医院. 核医学科，医学基因组学国家重点实验室，上海血液学研究所，上海 200025
    2b.上海交通大学医学院附属瑞金医院 病理科，医学基因组学国家重点实验室，上海血液学研究所，上海 200025
    2c.上海交通大学医学院附属瑞金医院　a. 核医学科；b病理科；c血液科，医学基因组学国家重点实验室，上海血液学研究所，上海 200025
李彪 E-mail：lb10363@rjh.com.cn

收稿日期: 2025-01-06

  录用日期: 2025-03-24

  网络出版日期: 2025-08-19

基金资助

上海申康医院发展中心临床科技创新项目(SHDC22023201)

收起

Prognostic value of PET/CT characteristics and combined IPI in follicular lymphoma and diffuse large B-cell lymphoma

  • LI Zhuohan ,
  • HUANG Xinyun ,
  • GUO Rui ,
  • YI Hongmei ,
  • XU Pengpeng ,
  • WU Zhifang ,
  • LI Biao
Expand
  • 1.Department of Nuclear Medicine, The First Hospital of Shanxi Medical University, Collaborative Innovation Center for Molecular Imaging, Shanxi Medical University, Taiyuan 030001, China
    2a.Department of Nuclear Medicine, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2b.Department of Nuclear Medicine, Department of Pathology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China
    2c.Department of Nuclear Medicine Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Centre for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2025-01-06

  Accepted date: 2025-03-24

  Online published: 2025-08-19

Fold

摘要

目的 国际预后指数（the international prognostic index， IPI）对合并滤泡性淋巴瘤成分的弥漫大B细胞淋巴瘤（follicular lymphoma and diffuse large B-cell lymphoma，FL/DLBCL）患者的危险区分效能有限，本研究旨在探索FL/DLBCL与DLBCL在影像学特征中的差异，并将PET/CT基线特征与临床参数融合，以优化IPI评价FL/DLBCL患者预后的效能。 方法 收集2015年1月至2022年1月在本院就诊并经病理证实的65例连续FL/DLBCL患者（随访时间2.4~113.0个月），按1∶1匹配一组同期诊断为DLBCL的患者（随访时间2.9~91.6个月），比较2组患者PET/CT影像特征及生存期的差异。应用Cox回归分析筛选FL/DLBCL患者无进展生存（progression‐free survival， PFS）期的独立预后因子，并纳入列线图。结合C指数（concordance index）和受试者操作特征（receiver operating characteristic，ROC）曲线评价模型的预测价值。结果 相较于DLBCL，FL/DLBCL患者PET/CT图像中的2个病灶之间最大距离（the largest distance between two lesions， Dmax）更大（55.07 cm比33.82 cm，P=0.031），全身病灶数量更多（7个比4个，P=0.002）。IPI评分能识别出低风险的FL/DLBCL患者（IPI评分为0～1）（P=0.010），但无法明确中低危、中高危或高危（IPI评分为2分、3分和4~5 分）的患者（P=0.743）。Cox回归分析证实，Dmax>73.08 cm（HR=3.151，95%CI为1.253～7.922，P=0.015）和IPI 2~5分（HR=3.285，95%CI为1.208～8.932，P=0.020）均是FL/DLBCL患者PFS期的独立预后因素。据此建立列线图构建新的预测模型，其C指数为0.701，新模型区分低危、中危和高危的能力，明显优于IPI（P=0.052），似然比检验、Wald 检验和得分检验均提示有较显著的统计学意义（χ2分别为13.27、12.88、15.11，P值分别为0.001、0.002、<0.001）。新模型预测FL/DLBCL患者2年PFS率的ROC曲线下面积（AUC）值为0.770，高于IPI的AUC值0.702（P<0.05）；预测2年总体生存（OS）率的AUC值0.827也显著优于IPI的AUC值0.745（P<0.05）。结论 FL/DLBCL在PET/CT图像上表现出比DLBCL更播散的特征；同时，Dmax是评估FL/DLBCL患者预后的十分有前景的参数，基于Dmax（>73.08 cm）和IPI（2~5分）构建的列线图在预测FL/DLBCL生存期时表现出很好的区分效能和预测准确性。

关键词： 国际预后指数; PET/CT; 弥漫大B细胞淋巴瘤; 滤泡性淋巴瘤; 预后

本文引用格式

李卓含 , 黄新韵 , 郭睿 , 易红梅 , 许彭鹏 , 武志芳 , 李彪 . 滤泡合并弥漫大B细胞淋巴瘤的PET/CT特征及其联合IPI在预后评估中的价值[J]. 诊断学理论与实践, 2025 , 24(02) : 178 -186 . DOI: 10.16150/j.1671-2870.2025.02.009

Abstract

Objective The international prognostic index (IPI) has limited ability to distinguish risk levels in patients with follicular lymphoma and diffuse large B-cell lymphoma (FL/DLBCL). This study aims to investigate the differences in imaging features between FL/DLBCL and DLBCL, and to integrate baseline PET/CT characteristics with clinical parameters to improve the prognostic efficiency of the IPI in FL/DLBCL patients. Methods A total of 65 consecutive patients with pathologically confirmed FL/DLBCL treated at our hospital between January 2015 and January 2022 were collected (follow-up duration: 2.4-113.0 months), and a 1∶ 1 matched group of patients diagnosed with DLBCL during the same period was selected (follow-up duration: 2.9-91.6 months). PET/CT features and survival differences between the two groups were compared. Cox regression analysis was used to identify independent prognostic factors for progression-free survival (PFS) in FL/DLBCL patients, which were incorporated into a nomogram. The predictive value of the model was evaluated using the concordance index (C-index) and receiver operating characteristic (ROC) curves. Results Compared with DLBCL, FL/DLBCL patients had a greater maximum distance between two lesions (Dmax) on PET/CT images (55.07 cm vs.33.82 cm, P=0.031) and a greater number of total lesions throughout the body (7 vs. 4, P=0.002). The IPI score could identify FL/DLBCL patients with low risk (IPI score 0-1) (P=0.010), but failed to identify patients with intermediate-low risk, intermediate-high risk or high risk (IPI score 2, 3 and 4-5) (P=0.743). Cox regression analysis confirmed that Dmax > 73.08 cm (HR = 3.151, 95% CI 1.253-7.922, P = 0.015) and IPI score 2-5 (HR = 3.285, 95% CI 1.208-8.932, P=0.020) were independent risk factors for PFS in FL/DLBCL patients. On this basis, a nomogram was constructed to demonstrate that the new model's hazard discrimination capability (P<0.001) significantly outperformed the IPI (P=0.052),with a Cindex of 0.701. The likelihood ratio test, Wald test and score test all demonstrated highly significant statistical significance (χ2 values were 13.27, 12.88, and 15.11, respectively, and P values were 0.001, 0.002, and <0.001, respectively). The area under the ROC curve (AUC) value predicted by the new model for the 2-year PFS rate in FL/DLBCL patients was 0.770, which was higher than the AUC value of 0.702 for IPI; The AUC value of 0.827 for predicting 2-year overall survival (OS) rate was also significantly better than the AUC value of 0.745 for IPI (P<0.05). Conclusion FL/DLBCL exhibits more disseminated characteristics on PET/CT images compared to DLBCL. Additionally, Dmax is a highly promising parameter for prognostic evaluation in FL/DLBCL, and the nomogram constructed based on Dmax >73.08 cm and IPI score of 2 to 5 demonstrates excellent discriminatory ability and predictive accuracy in predicting FL/DLBCL survival outcomes.

Key words： International prognostic index; PET/CT; Diffuse large B-cell lymphoma; Follicular lymphoma; Prognosis

参考文献

[1] 中国抗癌协会血液肿瘤专业委员会, 中华医学会血液学分会淋巴细胞疾病学组, 中国滤泡淋巴瘤工作组, 等. 中国滤泡性淋巴瘤诊断与治疗指南（2023年版）[J]. 中华血液学杂志,2023, 44(7):529-534.
  Hematology Oncology Committee of China Anti-Cancer Association; Lymphoid Disease Group, Chinese Society of Hematology, Chinese Medical Association; Chinese Wor-king Group of Follicular Lymphoma, et al. Chinese guidelines for diagnosis and treatment of follicular lymphoma(2023)[J]. Zhonghua Xue Ye Xue Za Zhi,2023, 44(7):529-534.
[2] REDDY N, OLUWOLE O, GREER J P, et al. Superior long-term outcome of patients with early transformation of non-Hodgkin lymphoma undergoing stem cell transplantation[J]. Clin Lymphoma Myeloma Leuk,2012, 12(6):406-411.
[3] DESAI S, CHATURVEDI M, HAMEED R, et al. Single-center analysis of characteristics and outcomes of de novo, concurrent, and transformed diffuse large B-cell lymphoma[J]. Oncologist, 2021, 26(9):e1660-e1663.
[4] ZHA J, FAN L, YI S, et al. Clinical features and outcomes of 1845 patients with follicular lymphoma: a real-world multicenter experience in China[J]. J Hematol Oncol,2021, 14(1):131.
[5] WANG Y, LINK B K, WITZIG T E, et al. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma[J]. Blood, 2019, 134(16):1289-1297.
[6] 林志娟, 查洁, 易树华, 等. 伴弥漫大B细胞成分的初诊滤泡淋巴瘤患者的临床特征及生存[J]. 中华血液学杂志,2022, 43(6):456-462.
  LIN Z J, ZHA J, YI S H, et al. Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component[J]. Zhonghua Xue Ye Xue Za Zhi,2022, 43:456-462
[7] LIM R M H, CHAN N P X, KHOO L P, et al. A clinico-genotypic prognostic index for de novo composite diffuse large B-cell lymphoma arising from follicular lymphoma in asian patients treated in the rituximab era[J]. Sci Rep, 2020, 10(1):4373.
[8] 中华医学会核医学分会. 淋巴瘤 18F-FDG PET/CT及PET/MR显像临床应用指南(2021版)[J]. 中华核医学与分子影像杂志,2021, 41(3):161-169.
  Chinese Society of Nuclear Medicine. Clinical practice guideline of 18F-FDG PET/CT and PET/MR in lymphoma (2021 edition)[J]. Chin J Nucl Med Mol Imaging,2021, 41(3):161-169.
[9] EL-GALALY T C, VILLA D, CHEAH C Y, et al. Pre-treatment total metabolic tumour volumes in lymphoma: Does quantity matter?[J]. Br J Haematol, 2022, 197(2):139-155.
[10] LI H, WANG M, ZHANG Y, et al. Prediction of prognosis and pathologic grade in follicular lymphoma using (18)F-FDG PET/CT[J]. Front Oncol, 2022, 12:943151.
[11] MEIGNAN M, COTTEREAU A S, VERSARI A, et al. Baseline metabolic tumor volume predicts outcome in high-tumor-burden follicular lymphoma: A pooled analysis of three multicenter studies[J]. J Clin Oncol, 2016, 34(30):3618-3626.
[12] COTTEREAU A S, MEIGNAN M, NIOCHE C, et al. Risk stratification in diffuse large B-cell lymphoma using lesion dissemination and metabolic tumor burden calculated from baseline PET/CT(?)[J]. Ann Oncol, 2021, 32(3):404-411.
[13] EERTINK J J, VAN DE BRUG T, WIEGERS S E, et al. (18)F-FDG PET baseline radiomics features improve the prediction of treatment outcome in diffuse large B-cell lymphoma[J]. Eur J Nucl Med Mol Imaging, 2022, 49(3):932-942.
[14] ZHANG X, CHEN L, JIANG H, et al. A novel analytic approach for outcome prediction in diffuse large B-cell lymphoma by [(18)F]FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2022, 49(4):1298-1310.
[15] EERTINK J J, ZWEZERIJNEN G J C, HEYMANS M W, et al. Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphoma[J]. Blood, 2023, 141(25):3055-3064.
[16] SWERDLOW S H, CAMPO E, PILERI S A, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016, 127(20):2375-2390.
[17] BOELLAARD R, DELGADO-BOLTON R, OYEN W J, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0[J]. Eur J Nucl Med Mol Ima-ging, 2015, 42(2):328-354.
[18] NIOCHE C, ORLHAC F, BOUGHDAD S, et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimoda-lity Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity[J]. Cancer Res, 2018, 78(16):4786-4789.
[19] WAHL R L, JACENE H, KASAMON Y, et al. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors[J]. J Nucl Med, 2009,50 (Suppl 1):122S-50S.
[20] COTTEREAU A S, NIOCHE C, DIRAND A S, et al. (18)F-FDG PET Dissemination Features in Diffuse Large B-Cell Lymphoma Are Predictive of Outcome[J]. J Nucl Med, 2020, 61(1):40-45.
[21] WANG F, CUI S, LU L, et al. Dissemination feature based on PET/CT is a risk factor for diffuse large B cell lymphoma patients outcome [J]. BMC Cancer, 2023, 23(1):1165.
[22] ZHANG Z. Propensity score method: a non-parametric technique to reduce model dependence[J]. Ann Transl Med, 2017, 5(1):7.
[23] VAUGHN J L, EPPERLA N. Survival of patients with transformed follicular lymphoma in the United States: a multiple cohort study[J]. Biomark Res, 2023, 11(1):84.
[24] MAGNANO L, BALAGUé O, DLOUHY I, et al. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma[J]. Ann Oncol, 2017, 28(11):2799-2805.
[25] CHEN Y, LUO L, CHEN L, et al. Clinical characteristics and prognosis of patients with co-existing follicular lymphoma and diffuse large B-cell lymphoma components in rituximab era[J]. J Cancer Res Clin Oncol, 2023, 149(6):2311-2318.
[26] URYU H, MISHIMA Y, TSUYAMA N, et al. Rituximab maintenance improves outcomes of transformed diffuse large B-cell lymphoma: a retrospective study of 519 cases with de novo diffuse large B-cell lymphoma and 62 cases with concurrent diffuse large B-cell lymphoma and follicular lymphoma[J]. Leuk Lymphoma, 2021, 62(9):2141-2150.
[27] ZHOU Z, SEHN L H, RADEMAKER A W, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era[J]. Blood, 2014, 123(6):837-842.
[28] MONTOTO S, LóPEZ-GUILLERMO A, ALTéS A, et al. Predictive value of Follicular Lymphoma International Prognostic Index (FLIPI) in patients with follicular lymphoma at first progression[J]. Ann Oncol, 2004, 15(10):1484-1489.
[29] FEDERICO M, BELLEI M, MARCHESELLI L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project[J]. J Clin Oncol, 2009, 27(27):4555-4562.
[30] GENG H, JIA S, ZHANG Y, et al. Efficacy and safety of zanubrutinib plus R-CHOP in treatment of non-GCB DLBCL with extranodal involvement[J]. Front Immunol, 2023, 14:1219167.
[31] NOWAKOWSKI G S, CHIAPPELLA A, GASCOYNE R D, et al. ROBUST: a phase Ⅲ study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma[J]. J Clin Oncol, 2021, 39(12):1317-1328.
[32] MADSEN C, PEDERSEN M B, VASE M, et al. Outcome determinants for transformed indolent lymphomas treated with or without autologous stem-cell transplantation[J]. Ann Oncol, 2015, 26(2):393-399.
[33] DESAI S H, LAPLANT B, MACON W R, et al. Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study[J]. Blood Cancer J, 2021, 11(9):160.
[34] DREYLING M, GHIELMINI M, RULE S, et al. Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2021, 32(3):298-308.
Options
文章导航

/

〈 〉